1. Scrip
  2. >>COVID-19

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

 
• By Joseph Haas

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

Coronavirus globe
Gilead's retrospective analysis of remdesivir needs to be backed up by a traditional study

Gilead Sciences, Inc. is trying to clear up lingering questions about its COVID-19 therapeutic remdesivir with a new retrospective comparative analysis of its SIMPLE-Severe study, including showing a mortality benefit, which had not been evident in data used for global clearances for emergency use of the antiviral. But the select use of data without a controlled trial is drawing criticism.

The Foster City, CA-based company got a small stock bounce on 10 July after releasing retrospective comparative analysis data measuring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.